Martin Emily Medlin, Messenger Kristen M, Sheats Mary Katherine, Jones Samuel L
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, United States.
Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, United States.
Front Vet Sci. 2017 Sep 28;4:160. doi: 10.3389/fvets.2017.00160. eCollection 2017.
Pro-inflammatory cytokines including tumor necrosis factor α (TNFα), IL-1β, IL-6, and IL-8 are potent immune mediators that exacerbate multiple equine diseases such as sepsis and laminitis. Unfortunately, safe and effective cytokine-targeting therapies are lacking in horses; therefore, novel mechanisms of inhibiting cytokine production are critically needed. One potential mechanism for inhibiting cytokine synthesis is elevation of intracellular cyclic AMP (cAMP). In human leukocytes, intracellular cAMP production is induced by activation of E-prostanoid (EP) receptors 2 and 4. These receptors can be targeted by the EP2/4 agonist and prostaglandin E analog, misoprostol. Misoprostol is currently used as a gastroprotectant in horses but has not been evaluated as a cytokine-targeting therapeutic. Thus, we hypothesized that misoprostol treatment would inhibit pro-inflammatory cytokine production by lipopolysaccharide (LPS)-stimulated equine leukocytes in an inflammation model. To test this hypothesis, equine leukocyte-rich plasma (LRP) was collected from 12 healthy adult horses and used to model LPS-mediated inflammatory signaling. LRP was treated with varying concentrations of misoprostol either (pretreated) or (posttreated) LPS stimulation. LRP supernatants were assayed for 23 cytokines using an equine-specific multiplex bead immunoassay. Leukocytes were isolated from LRP, and leukocyte mRNA levels of four important cytokines were evaluated RT-PCR. Statistical differences between treatments were determined using one-way RM ANOVA (Holm-Sidak testing) or Friedman's RM ANOVA on Ranks (SNK testing), where appropriate ( < 0.05, = 3-6 horses). These studies revealed that misoprostol pre- and posttreatment inhibited LPS-induced TNFα and IL-6 protein production in equine leukocytes but had no effect on IL-8 protein. Interestingly, misoprostol pretreatment enhanced IL-1β protein synthesis following 6 h of LPS stimulation, while misoprostol posttreatment inhibited IL-1β protein production after 24 h of LPS stimulation. At the mRNA level, misoprostol pre- and posttreatment inhibited LPS-induced TNFα, IL-1β, and IL-6 mRNA production but did not affect IL-8 mRNA. These results indicate that misoprostol exerts anti-inflammatory effects on equine leukocytes when applied before or after a pro-inflammatory stimulus. However, the effects we observed were cytokine-specific and sometimes differed at the mRNA and protein levels. Further studies are warranted to establish the inhibitory effects of misoprostol on equine cytokine production .
包括肿瘤坏死因子α(TNFα)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)和白细胞介素-8(IL-8)在内的促炎细胞因子是强效免疫介质,可加剧多种马类疾病,如败血症和蹄叶炎。不幸的是,马匹缺乏安全有效的细胞因子靶向治疗方法;因此,迫切需要抑制细胞因子产生的新机制。抑制细胞因子合成的一种潜在机制是细胞内环状单磷酸腺苷(cAMP)水平升高。在人类白细胞中,E-前列腺素(EP)受体2和4的激活可诱导细胞内cAMP产生。这些受体可被EP2/4激动剂和前列腺素E类似物米索前列醇靶向作用。米索前列醇目前在马匹中用作胃黏膜保护剂,但尚未作为细胞因子靶向治疗药物进行评估。因此,我们假设在炎症模型中,米索前列醇治疗可抑制脂多糖(LPS)刺激的马类白细胞产生促炎细胞因子。为验证这一假设,从12匹健康成年马采集富含白细胞的血浆(LRP),用于模拟LPS介导的炎症信号传导。LRP在LPS刺激前(预处理)或后(后处理)用不同浓度的米索前列醇处理。使用马类特异性多重微珠免疫测定法检测LRP上清液中的23种细胞因子。从LRP中分离白细胞,通过逆转录聚合酶链反应(RT-PCR)评估四种重要细胞因子的白细胞mRNA水平。在适当情况下,使用单向重复测量方差分析(Holm-Sidak检验)或Friedman秩和重复测量方差分析(SNK检验)确定处理组之间的统计学差异(P<0.05,每组n = 3 - 6匹马)。这些研究表明,米索前列醇预处理和后处理均抑制LPS诱导的马类白细胞中TNFα和IL-6蛋白的产生,但对IL-8蛋白无影响。有趣的是,米索前列醇预处理在LPS刺激6小时后增强了IL-1β蛋白的合成,而米索前列醇后处理在LPS刺激24小时后抑制了IL-1β蛋白的产生。在mRNA水平上,米索前列醇预处理和后处理均抑制LPS诱导的TNFα、IL-1β和IL-6 mRNA的产生,但不影响IL-8 mRNA。这些结果表明,在促炎刺激之前或之后应用米索前列醇对马类白细胞具有抗炎作用。然而,我们观察到的效果具有细胞因子特异性,并且在mRNA和蛋白水平上有时存在差异。有必要进一步研究以确定米索前列醇对马类细胞因子产生的抑制作用。